When diagnosed with prostate cancer, men with limited life expectancy are being overtreated, according to a study published Nov. 11 in JAMA Internal Medicine. Researchers from Los Angeles-based Cedars ...

About 1 in 8 men will get prostate cancer in their lifetime. But a new study concludes an increasing number of men with limited life expectancy are being overtreated for the disease with procedures ...

Overtreatment of older prostate cancer patients with a limited life expectancy has increased over the past two decades among men receiving care in the Veterans Affairs (VA) health system, researchers ...

Clinicians must appropriately assess life expectancy and take steps to avoid prostate cancer overtreatment. Even in the active surveillance era, overtreatment persists among men with limited life ...

Dr. William Russell specializes in radiation oncology in Baton Rouge. He graduated from the University of Mississippi School of Medicine in 1984. Russell is double-board certified in internal medicine ...

Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients with undetectable PSA levels.

New research in JNCCN—Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated according to NCCN ...

Black men choose aggressive prostate cancer treatment—regardless of anticipated life expectancy—more often than Hispanic or Caucasian men, according to new research by Cedars-Sinai investigators ...

National guidelines from associations such as the National Comprehensive Cancer Network (NCCN) and the American Urological Association recommend that men with a life expectancy of less than 10 years ...